{"id":3303,"date":"2021-11-23T15:53:54","date_gmt":"2021-11-23T14:53:54","guid":{"rendered":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/?p=3303"},"modified":"2022-04-27T14:58:00","modified_gmt":"2022-04-27T12:58:00","slug":"deja-11-travaux-publies-en-2021","status":"publish","type":"post","link":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/deja-11-travaux-publies-en-2021\/","title":{"rendered":"D\u00e9j\u00e0 11 travaux publi\u00e9s en 2021\u00a0!"},"content":{"rendered":"

D\u00e9j\u00e0 11 travaux publi\u00e9s en 2021\u00a0!<\/strong><\/p>\n

H\u00e9patite virale C\u00a0: <\/strong><\/p>\n

Au cours des 4 derni\u00e8res ann\u00e9es, plusieurs \u00e9tudes ont port\u00e9 sur l’identification ou la pr\u00e9diction du carcinome h\u00e9patocellulaire chez les patients infect\u00e9s par l’h\u00e9patite C, avant ou apr\u00e8s la gu\u00e9rison virologique. La biobanque de cohorte a, entre autre, \u00e9t\u00e9 utilis\u00e9e pour la validation externe d’un biomarqueur de CHC (LCR1-LCR2) montrant d’excellentes performances pour discriminer les patients \u00e0 haut risque des patients \u00e0 faible risque.<\/p>\n

Par ailleurs, en collaboration avec la cohorte ANRS-CO13 HEPAVIH (Linda Wittkop, Bordeaux), plusieurs \u00e9tudes ont \u00e9t\u00e9 men\u00e9es pour explorer et comparer les r\u00e9sultats cliniques des patients VIH\/VHC par rapport aux patients mono-infect\u00e9s. L’\u00e9tude des \u00e9tudes montre un risque plus \u00e9lev\u00e9 de d\u00e9c\u00e8s toutes causes confondues, de d\u00e9c\u00e8s non li\u00e9s au foie et de cancers non li\u00e9s au foie chez les participants co-infect\u00e9s par le virus de l’immunod\u00e9ficience humaine et le virus de l’h\u00e9patite C, et aucune diff\u00e9rence pour le risque de d\u00e9c\u00e8s ou d’\u00e9v\u00e9nements li\u00e9s au foie, apr\u00e8s traitement par antiviraux directs (AVD).<\/p>\n

Enfin, plusieurs analyses ont \u00e9t\u00e9 r\u00e9alis\u00e9es par l’\u00e9quipe de Patrizia Carrieri. Une importante \u00e9tude collaborative visait \u00e0 d\u00e9terminer si l’efficacit\u00e9 des antiviraux \u00e0 action directe diff\u00e9rait entre les migrants – une population socialement vuln\u00e9rable – et les non-migrants. Nos r\u00e9sultats ont montr\u00e9 un risque plus \u00e9lev\u00e9 d’\u00e9chec du traitement chez les migrants d’Asie centrale que chez les non-migrants. Cela sugg\u00e8re la n\u00e9cessit\u00e9 de mettre en place des strat\u00e9gies de traitement et de soins sur mesure pour cette population. La figure montre le risque d’\u00e9chec du traitement en fonction du statut de migrant chez les patients de la cohorte.<\/p>\n

\u00a0<\/strong><\/p>\n

H\u00e9patite virale B<\/strong><\/p>\n

Bien que les analogues nucl\u00e9os(t)idiques aient \u00e9t\u00e9 clairement associ\u00e9s \u00e0 une r\u00e9duction des complications, de r\u00e9centes m\u00e9ta-analyses d’\u00e9tudes de cohorte asiatiques sugg\u00e8rent que le t\u00e9nofovir pourrait \u00eatre associ\u00e9 \u00e0 un risque r\u00e9duit de Carcinome H\u00e9patoCellulaire (CHC) ainsi qu’\u00e0 un risque plus faible de cirrhose d\u00e9compens\u00e9e ou de d\u00e9c\u00e8s li\u00e9s au foie par rapport \u00e0 l’ent\u00e9cavir. L’objectif d\u2019une des \u00e9tudes \u00e9tait de comparer prospectivement les r\u00e9sultats du t\u00e9nofovir et de l’ent\u00e9cavir sur cinq issues (CHC, cirrhose d\u00e9compens\u00e9e, transplantation h\u00e9patique, toutes causes de d\u00e9c\u00e8s et d\u00e9c\u00e8s li\u00e9s au foie) ainsi qu’un crit\u00e8re composite combinant l’une ou l’autre de ces issues, chez des patients. Tous les patients atteints d’une infection par le VHB et ayant re\u00e7u du t\u00e9nofovir ou de l’ent\u00e9cavir pendant plus de 6 mois \u00e0 l’entr\u00e9e ou apr\u00e8s l’entr\u00e9e dans la cohorte ont \u00e9t\u00e9 s\u00e9lectionn\u00e9s. Les patients pr\u00e9sentant une co-infection par le VHD et le VHC ou un \u00e9v\u00e9nement h\u00e9patique ant\u00e9rieur ont \u00e9t\u00e9 exclus. Le risque d’\u00e9v\u00e9nements li\u00e9s au foie ou de d\u00e9c\u00e8s n’\u00e9tait pas diff\u00e9rent entre les patients trait\u00e9s au t\u00e9nofovir et ceux trait\u00e9s \u00e0 l’ent\u00e9cavir et nous n’avons pas trouv\u00e9 de diff\u00e9rence entre les traitements.<\/p>\n

Nous avons par ailleurs entrepris une exploration des facteurs de risque du carcinome h\u00e9patocellulaire (CHC) chez les patients atteints d’une infection chronique par le VHB. Les objectifs de cette \u00e9tude \u00e9taient : 1) de proposer un mod\u00e8le d’\u00e9quations structurelles (SEM) qui sch\u00e9matise les relations causales entre les caract\u00e9ristiques des patients infect\u00e9s par le VHB chronique et la survenue du CHC, y compris les effets directs et indirects (c’est-\u00e0-dire m\u00e9di\u00e9s), 2) d’identifier et de quantifier les risques de survenue du CHC associ\u00e9s aux caract\u00e9ristiques cliniques, biologiques et th\u00e9rapeutiques des patients infect\u00e9s par le VHB. Cette \u00e9tude exploratoire a \u00e9t\u00e9 limit\u00e9e par un faible nombre de CHC incidents. Avec plus d’\u00e9v\u00e9nements rapport\u00e9s aujourd’hui, nous allons poursuivre l’exploration des facteurs de risque pour le d\u00e9veloppement du CHC chez les patients trait\u00e9s par le VHB.<\/p>\n

Letter: tenofovir may be superior to entecavir for treatment-na\u00efve chronic hepatitis B patients-authors’ reply<\/strong>.<\/p>\n

Pol S & al.<\/p>\n

Aliment Pharmacol Ther<\/em>. 2021 May;53(9):1050.doi: 10.1111\/apt.16340.<\/p>\n

Predictive Factors for Hepatocellular Carcinoma in Chronic Hepatitis B Using Structural Equation Modeling: A Prospective Cohort Study. <\/strong><\/p>\n

Lam L & al.<\/p>\n

Clin Res Hepatol Gastroenterol<\/em>. 2021 Apr 27;45(5):101713.doi: 10.1016\/j.clinre.2021.101713.<\/p>\n

Similar 5-year HCC occurrence in Tenofovir- and Entecavir-treated HBV chronic infection in the French AFEF\/ANRS CO22 Hepather cohort.<\/strong><\/p>\n

Pol S & al.<\/p>\n

Aliment Pharmacol Ther<\/em>. 2021 Mar;53(5):616-629.doi: 10.1111\/apt.16197.<\/p>\n

Editorial: similar risk of hepatocellular carcinoma in chronic hepatitis B patients treated with tenofovir or entecavir-new clues from Europe. Authors’ reply.<\/strong><\/p>\n

Pol S & al.<\/p>\n

Aliment Pharmacol Ther<\/em>. 2021 Mar;53(5):659.doi: 10.1111\/apt.16251.<\/p>\n

Liver fibrosis and all-cause mortality in chronic HCV-infected diabetic patients: a paradoxical association? (ANRS CO22 HEPATHER). <\/strong><\/p>\n

Barr\u00e9 T & al.<\/p>\n

Liver Int<\/em>. 2021 Jul;41(7):1694-1698.doi: 10.1111\/liv.14949. Epub 2021 May 28.<\/p>\n

Social vulnerability of patients co-infected with hepatitis B and hepatitis delta viruses: Data from the ANRS CO22 HEPATHER cohort. <\/strong><\/p>\n

Marcellin F\u00a0 & al.<\/p>\n

J Clin Virol<\/em> 2021 doi.org\/10.1016\/j.jcv.2021.104987<\/a><\/p>\n

\u00a0<\/strong><\/p>\n

Late presentation for HCV care: time to target people with diabetes and\/or hazardous alcohol use (ANRS CO22 HEPATHER cohort)<\/strong>.<\/p>\n

Santos M & al.<\/p>\n

Liver Int<\/em>. 2021 PMID: 34520614 DOI: 10.1111\/liv.15056<\/a><\/p>\n

\u00a0<\/strong><\/p>\n

External validation of LCR1-LCR2, a multivariable HCC risk calculator, in patients with chronic HCV. <\/strong><\/p>\n

Poynard T & al.<\/p>\n

JHEP Rep<\/em>. 2021 Apr 24;3(4):100298.doi: 10.1016\/j.jhepr.2021.100298. eCollection 2021 Aug.<\/p>\n

Effectiveness of direct-acting antivirals for chronic hepatitis C treatment in migrant and non-migrant populations in France.<\/strong><\/p>\n

Djaogol T & al.<\/p>\n

Liver Int<\/em>. 2021 Feb 16.doi: 10.1111\/liv.14823<\/p>\n

Increased mortality in HIV\/HCV-coinfected compared to HCV-monoinfected patients in the DAA era due to non-liver-related death<\/strong>.<\/p>\n

Chalouni M & al.<\/p>\n

J Hepatol<\/em>. 2021 Jan;74(1):37-47. doi: 10.1016\/j.jhep.2020.08.008. Epub 2020 Aug 14.<\/p>\n

Direct, indirect and total effect of HIV coinfection on the risk of non-liver-related cancer in hepatitis C virus-infected patients treated by direct-acting antivirals: a mediation analysis<\/strong>.<\/p>\n

Chalouni M & al<\/p>\n

HIV Med<\/em>. 2021 Aug 17. doi: 10.1111\/hiv.13153<\/p>\n

Absence of impact of direct acting antivirals for hepatitis C virus on recurrent hepatocellular carcinoma tumor growth in the AFEF\/ANRS CO22 Hepather cohort.<\/strong><\/p>\n

Vallet-Pichard A & al.<\/p>\n

Clin Res Hepatol Gastroenterol<\/em>. 2021 Jan;45(1):101459.doi: 10.1016\/j.clinre.2020.04.022. Epub 2020 Jun 25.<\/p>\n","protected":false},"excerpt":{"rendered":"

D\u00e9j\u00e0 11 travaux publi\u00e9s en 2021\u00a0! H\u00e9patite virale C\u00a0: Au cours des 4 derni\u00e8res ann\u00e9es, plusieurs \u00e9tudes ont port\u00e9 sur l’identification ou la pr\u00e9diction du carcinome h\u00e9patocellulaire chez les patients infect\u00e9s par l’h\u00e9patite C, avant ou apr\u00e8s la gu\u00e9rison virologique. La biobanque de cohorte a, entre autre, \u00e9t\u00e9 utilis\u00e9e pour la validation externe d’un biomarqueur […]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_bbp_topic_count":0,"_bbp_reply_count":0,"_bbp_total_topic_count":0,"_bbp_total_reply_count":0,"_bbp_voice_count":0,"_bbp_anonymous_reply_count":0,"_bbp_topic_count_hidden":0,"_bbp_reply_count_hidden":0,"_bbp_forum_subforum_count":0,"jetpack_post_was_ever_published":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[2],"tags":[],"class_list":["post-3303","post","type-post","status-publish","format-standard","hentry","category-actualites"],"yoast_head":"\nD\u00e9j\u00e0 11 travaux publi\u00e9s en 2021\u00a0! - ANRS CO22 HEPATHER<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/deja-11-travaux-publies-en-2021\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"D\u00e9j\u00e0 11 travaux publi\u00e9s en 2021\u00a0! - ANRS CO22 HEPATHER\" \/>\n<meta property=\"og:description\" content=\"D\u00e9j\u00e0 11 travaux publi\u00e9s en 2021\u00a0! H\u00e9patite virale C\u00a0: Au cours des 4 derni\u00e8res ann\u00e9es, plusieurs \u00e9tudes ont port\u00e9 sur l’identification ou la pr\u00e9diction du carcinome h\u00e9patocellulaire chez les patients infect\u00e9s par l’h\u00e9patite C, avant ou apr\u00e8s la gu\u00e9rison virologique. La biobanque de cohorte a, entre autre, \u00e9t\u00e9 utilis\u00e9e pour la validation externe d’un biomarqueur […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/deja-11-travaux-publies-en-2021\/\" \/>\n<meta property=\"og:site_name\" content=\"ANRS CO22 HEPATHER\" \/>\n<meta property=\"article:published_time\" content=\"2021-11-23T14:53:54+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-04-27T12:58:00+00:00\" \/>\n<meta name=\"author\" content=\"admin_fchau\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin_fchau\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/deja-11-travaux-publies-en-2021\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/deja-11-travaux-publies-en-2021\/\"},\"author\":{\"name\":\"admin_fchau\",\"@id\":\"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/#\/schema\/person\/4f3fad5bed1296bc8d2682e255b04363\"},\"headline\":\"D\u00e9j\u00e0 11 travaux publi\u00e9s en 2021\u00a0!\",\"datePublished\":\"2021-11-23T14:53:54+00:00\",\"dateModified\":\"2022-04-27T12:58:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/deja-11-travaux-publies-en-2021\/\"},\"wordCount\":1077,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/#organization\"},\"articleSection\":[\"Actualit\u00e9s\"],\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/deja-11-travaux-publies-en-2021\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/deja-11-travaux-publies-en-2021\/\",\"url\":\"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/deja-11-travaux-publies-en-2021\/\",\"name\":\"D\u00e9j\u00e0 11 travaux publi\u00e9s en 2021\u00a0! - ANRS CO22 HEPATHER\",\"isPartOf\":{\"@id\":\"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/#website\"},\"datePublished\":\"2021-11-23T14:53:54+00:00\",\"dateModified\":\"2022-04-27T12:58:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/deja-11-travaux-publies-en-2021\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/deja-11-travaux-publies-en-2021\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/deja-11-travaux-publies-en-2021\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"D\u00e9j\u00e0 11 travaux publi\u00e9s en 2021\u00a0!\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/#website\",\"url\":\"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/\",\"name\":\"ANRS CO22 HEPATHER\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/#organization\",\"name\":\"IPLESP UMRS 1136\",\"url\":\"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/i0.wp.com\/triton.iplesp.upmc.fr\/hepather_ANRS\/wp-content\/uploads\/2019\/02\/logoTagline_anrs_white.png?fit=464%2C175&ssl=1\",\"contentUrl\":\"https:\/\/i0.wp.com\/triton.iplesp.upmc.fr\/hepather_ANRS\/wp-content\/uploads\/2019\/02\/logoTagline_anrs_white.png?fit=464%2C175&ssl=1\",\"width\":464,\"height\":175,\"caption\":\"IPLESP UMRS 1136\"},\"image\":{\"@id\":\"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/#\/schema\/person\/4f3fad5bed1296bc8d2682e255b04363\",\"name\":\"admin_fchau\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/229bc5b382de71dd7adf24bf63db3daa512e04799f95a6001d5b0fc32df093c6?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/229bc5b382de71dd7adf24bf63db3daa512e04799f95a6001d5b0fc32df093c6?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/229bc5b382de71dd7adf24bf63db3daa512e04799f95a6001d5b0fc32df093c6?s=96&d=mm&r=g\",\"caption\":\"admin_fchau\"},\"url\":\"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/author\/admin_fchau\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"D\u00e9j\u00e0 11 travaux publi\u00e9s en 2021\u00a0! - ANRS CO22 HEPATHER","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/deja-11-travaux-publies-en-2021\/","og_locale":"fr_FR","og_type":"article","og_title":"D\u00e9j\u00e0 11 travaux publi\u00e9s en 2021\u00a0! - ANRS CO22 HEPATHER","og_description":"D\u00e9j\u00e0 11 travaux publi\u00e9s en 2021\u00a0! H\u00e9patite virale C\u00a0: Au cours des 4 derni\u00e8res ann\u00e9es, plusieurs \u00e9tudes ont port\u00e9 sur l’identification ou la pr\u00e9diction du carcinome h\u00e9patocellulaire chez les patients infect\u00e9s par l’h\u00e9patite C, avant ou apr\u00e8s la gu\u00e9rison virologique. La biobanque de cohorte a, entre autre, \u00e9t\u00e9 utilis\u00e9e pour la validation externe d’un biomarqueur […]","og_url":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/deja-11-travaux-publies-en-2021\/","og_site_name":"ANRS CO22 HEPATHER","article_published_time":"2021-11-23T14:53:54+00:00","article_modified_time":"2022-04-27T12:58:00+00:00","author":"admin_fchau","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"admin_fchau","Dur\u00e9e de lecture estim\u00e9e":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/deja-11-travaux-publies-en-2021\/#article","isPartOf":{"@id":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/deja-11-travaux-publies-en-2021\/"},"author":{"name":"admin_fchau","@id":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/#\/schema\/person\/4f3fad5bed1296bc8d2682e255b04363"},"headline":"D\u00e9j\u00e0 11 travaux publi\u00e9s en 2021\u00a0!","datePublished":"2021-11-23T14:53:54+00:00","dateModified":"2022-04-27T12:58:00+00:00","mainEntityOfPage":{"@id":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/deja-11-travaux-publies-en-2021\/"},"wordCount":1077,"commentCount":0,"publisher":{"@id":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/#organization"},"articleSection":["Actualit\u00e9s"],"inLanguage":"fr-FR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/deja-11-travaux-publies-en-2021\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/deja-11-travaux-publies-en-2021\/","url":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/deja-11-travaux-publies-en-2021\/","name":"D\u00e9j\u00e0 11 travaux publi\u00e9s en 2021\u00a0! - ANRS CO22 HEPATHER","isPartOf":{"@id":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/#website"},"datePublished":"2021-11-23T14:53:54+00:00","dateModified":"2022-04-27T12:58:00+00:00","breadcrumb":{"@id":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/deja-11-travaux-publies-en-2021\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/deja-11-travaux-publies-en-2021\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/deja-11-travaux-publies-en-2021\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/"},{"@type":"ListItem","position":2,"name":"D\u00e9j\u00e0 11 travaux publi\u00e9s en 2021\u00a0!"}]},{"@type":"WebSite","@id":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/#website","url":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/","name":"ANRS CO22 HEPATHER","description":"","publisher":{"@id":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/#organization","name":"IPLESP UMRS 1136","url":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/#\/schema\/logo\/image\/","url":"https:\/\/i0.wp.com\/triton.iplesp.upmc.fr\/hepather_ANRS\/wp-content\/uploads\/2019\/02\/logoTagline_anrs_white.png?fit=464%2C175&ssl=1","contentUrl":"https:\/\/i0.wp.com\/triton.iplesp.upmc.fr\/hepather_ANRS\/wp-content\/uploads\/2019\/02\/logoTagline_anrs_white.png?fit=464%2C175&ssl=1","width":464,"height":175,"caption":"IPLESP UMRS 1136"},"image":{"@id":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/#\/schema\/person\/4f3fad5bed1296bc8d2682e255b04363","name":"admin_fchau","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/229bc5b382de71dd7adf24bf63db3daa512e04799f95a6001d5b0fc32df093c6?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/229bc5b382de71dd7adf24bf63db3daa512e04799f95a6001d5b0fc32df093c6?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/229bc5b382de71dd7adf24bf63db3daa512e04799f95a6001d5b0fc32df093c6?s=96&d=mm&r=g","caption":"admin_fchau"},"url":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/author\/admin_fchau\/"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/paQKc4-Rh","jetpack-related-posts":[{"id":3290,"url":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/4-travaux-publies-en-2019-dans-le-domaine-de-lhepatite-virale-c\/","url_meta":{"origin":3303,"position":0},"title":"4 travaux publi\u00e9s en 2019 dans le domaine de l\u2019h\u00e9patite virale C","author":"admin_fchau","date":"3 novembre 2019","format":false,"excerpt":"4 travaux publi\u00e9s en 2019 dans le domaine de l\u2019h\u00e9patite virale C \u00a0 A notre connaissance, l'\u00e9tude de cohorte ANRS CO22 Hepather a \u00e9t\u00e9 la premi\u00e8re \u00e9tude longitudinale prospective \u00e0 explorer les r\u00e9sultats cliniques associ\u00e9s au traitement par anti-viraux directs (AVD) chez les patients atteints d'h\u00e9patite C chronique, en comparant\u2026","rel":"","context":"Dans "Actualit\u00e9s"","block_context":{"text":"Actualit\u00e9s","link":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/category\/actualites\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":3372,"url":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/2022-15-travaux-publies-a-partir-des-donnees-de-la-cohorte-hepather\/","url_meta":{"origin":3303,"position":1},"title":"2022. 15 travaux publi\u00e9s \u00e0 partir des donn\u00e9es de la cohorte HEPATHER !","author":"admin_fchau","date":"17 d\u00e9cembre 2022","format":false,"excerpt":"Ces \u00e9tudes apportent des avanc\u00e9es importantes dans la compr\u00e9hension des h\u00e9patites virales B et C et de leurs complications, notamment en mati\u00e8re de d\u00e9pistage pr\u00e9coce, de facteurs de risque et de strat\u00e9gies pr\u00e9ventives.Plusieurs \u00e9tudes r\u00e9alis\u00e9es par l'\u00e9quipe de sciences sociales du SESSTIM (Inserm, Universit\u00e9 Aix Marseille et IRD) ont port\u00e9\u2026","rel":"","context":"Dans "Actualit\u00e9s"","block_context":{"text":"Actualit\u00e9s","link":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/category\/actualites\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":3206,"url":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/7-travaux-issus-de-la-cohorte-seront-presentes-au-congres-americain-de-lamerican-association-for-the-study-of-liver-diseases-aasld-en-novembre-2019\/","url_meta":{"origin":3303,"position":2},"title":"7 travaux issus de la cohorte seront pr\u00e9sent\u00e9s au congr\u00e8s am\u00e9ricain de l\u2019American Association for the Study of Liver Diseases (AASLD) en novembre 2019\u00a0!","author":"C\u00e9line Dorival Mouly","date":"9 septembre 2019","format":false,"excerpt":"Diff\u00e9rentes \u00e9tudes issues des donn\u00e9es de la cohorte HEPATHER seront pr\u00e9sent\u00e9s au congr\u00e8s de l\u2019AASLD qui se d\u00e9roule du 8 au 12 novembre 2019 \u00e0 Boston. \u00a0 1 travail sera pr\u00e9sent\u00e9 \u00e0 l\u2019oral \u00a0: Lors de la session parall\u00e8le 28 le lundi 11 novembre \u00e0 11h30 (Ballroom A) L\u2019impact sur\u2026","rel":"","context":"Dans "Non class\u00e9"","block_context":{"text":"Non class\u00e9","link":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/category\/non-classe\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":3393,"url":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/2024-une-annee-de-preparation-et-de-transition-3-publications-par-lequipe-du-sesstim\/","url_meta":{"origin":3303,"position":3},"title":"2024 – une ann\u00e9e de pr\u00e9paration et de transition. 3 publications par l’\u00e9quipe du SESSTIM.","author":"admin_fchau","date":"17 mars 2025","format":false,"excerpt":"L'ann\u00e9e 2024 a \u00e9t\u00e9 marqu\u00e9e par la pr\u00e9paration de la suite de la cohorte HEPATHER dont la date de fin \u00e9tait programm\u00e9e au 31 d\u00e9cembre 2024.Hepat-B proposera de prolonger le suivi des patients atteints d'h\u00e9patite B inclus dans Hepather jusqu'en 2029, avec la r\u00e9alisation de nouvelles collections biologiques. Cette cohorte\u2026","rel":"","context":"Dans "Actualit\u00e9s"","block_context":{"text":"Actualit\u00e9s","link":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/category\/actualites\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":3297,"url":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/7-travaux-publies-en-2020-dans-le-domaine-des-hepatites-virales-b-et-c\/","url_meta":{"origin":3303,"position":4},"title":"7 travaux publi\u00e9s en 2020 dans le domaine des h\u00e9patites virales B et C","author":"admin_fchau","date":"23 novembre 2020","format":false,"excerpt":"7 travaux publi\u00e9s en 2020 dans le domaine des h\u00e9patites virales B et C \u00a0 \u00a0 Sofosbuvir-Daclatasvir is suboptimal in patients with genotype 2 chronic hepatitis C infection: real-life experience from the HEPATHER ANRS CO22 cohort. De Ledinghen V & al. J Viral Hepat. 2020 Oct;27(10):964-973. doi: 10.1111\/jvh.13321. Epub 2020\u2026","rel":"","context":"Dans "Actualit\u00e9s"","block_context":{"text":"Actualit\u00e9s","link":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/category\/actualites\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":3376,"url":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/2023-premiers-travaux-issus-du-chainage-individuel-des-donnees-de-la-cohorte-hepather-avec-le-systeme-national-des-donnees-de-sante-5-publications\/","url_meta":{"origin":3303,"position":5},"title":"2023 – Premiers travaux issus du cha\u00eenage individuel des donn\u00e9es de la cohorte Hepather avec le Syst\u00e8me National des Donn\u00e9es de Sant\u00e9. 5 publications","author":"admin_fchau","date":"17 d\u00e9cembre 2024","format":false,"excerpt":"Le cha\u00eenage avec les donn\u00e9es du Syst\u00e8me National des Donn\u00e9es de Sant\u00e9 (SDNS) autoris\u00e9 par la commission nationale informatique et libert\u00e9 en 2018 a \u00e9t\u00e9 r\u00e9alis\u00e9 pour plus de 80% des participants de la cohorte qui ont donn\u00e9 leur consentement, \u00e0 partir de la reconstruction du num\u00e9ro d'identification au r\u00e9pertoire\u2026","rel":"","context":"Dans "Actualit\u00e9s"","block_context":{"text":"Actualit\u00e9s","link":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/category\/actualites\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]}],"_links":{"self":[{"href":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/wp-json\/wp\/v2\/posts\/3303","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/wp-json\/wp\/v2\/comments?post=3303"}],"version-history":[{"count":2,"href":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/wp-json\/wp\/v2\/posts\/3303\/revisions"}],"predecessor-version":[{"id":3324,"href":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/wp-json\/wp\/v2\/posts\/3303\/revisions\/3324"}],"wp:attachment":[{"href":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/wp-json\/wp\/v2\/media?parent=3303"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/wp-json\/wp\/v2\/categories?post=3303"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/wp-json\/wp\/v2\/tags?post=3303"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}